JP5046952B2 - 核酸送達用キャリアー組成物 - Google Patents

核酸送達用キャリアー組成物 Download PDF

Info

Publication number
JP5046952B2
JP5046952B2 JP2007540975A JP2007540975A JP5046952B2 JP 5046952 B2 JP5046952 B2 JP 5046952B2 JP 2007540975 A JP2007540975 A JP 2007540975A JP 2007540975 A JP2007540975 A JP 2007540975A JP 5046952 B2 JP5046952 B2 JP 5046952B2
Authority
JP
Japan
Prior art keywords
nucleic acid
acid delivery
composition
carrier composition
oil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007540975A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2007046356A1 (ja
Inventor
秀一 豊福
英男 宮尾
正子 佐藤
和生 関口
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Priority to JP2007540975A priority Critical patent/JP5046952B2/ja
Publication of JPWO2007046356A1 publication Critical patent/JPWO2007046356A1/ja
Application granted granted Critical
Publication of JP5046952B2 publication Critical patent/JP5046952B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2007540975A 2005-10-18 2006-10-17 核酸送達用キャリアー組成物 Expired - Fee Related JP5046952B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2007540975A JP5046952B2 (ja) 2005-10-18 2006-10-17 核酸送達用キャリアー組成物

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2005303497 2005-10-18
JP2005303497 2005-10-18
JP2007540975A JP5046952B2 (ja) 2005-10-18 2006-10-17 核酸送達用キャリアー組成物
PCT/JP2006/320617 WO2007046356A1 (ja) 2005-10-18 2006-10-17 核酸送達用キャリアー組成物

Publications (2)

Publication Number Publication Date
JPWO2007046356A1 JPWO2007046356A1 (ja) 2009-04-23
JP5046952B2 true JP5046952B2 (ja) 2012-10-10

Family

ID=37962449

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007540975A Expired - Fee Related JP5046952B2 (ja) 2005-10-18 2006-10-17 核酸送達用キャリアー組成物

Country Status (19)

Country Link
US (1) US8030075B2 (https=)
EP (1) EP1946761B8 (https=)
JP (1) JP5046952B2 (https=)
KR (1) KR101324065B1 (https=)
CN (2) CN101291678B (https=)
AR (1) AR057553A1 (https=)
AU (1) AU2006305318B2 (https=)
BR (1) BRPI0617449A2 (https=)
CA (1) CA2624840A1 (https=)
CY (1) CY1114586T1 (https=)
DK (1) DK1946761T3 (https=)
ES (1) ES2412029T3 (https=)
MY (1) MY149502A (https=)
PL (1) PL1946761T3 (https=)
PT (1) PT1946761E (https=)
RU (1) RU2421227C2 (https=)
SI (1) SI1946761T1 (https=)
TW (1) TW200800235A (https=)
WO (1) WO2007046356A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200800235A (en) * 2005-10-18 2008-01-01 Otsuka Pharma Co Ltd Carrier composition for nucleic acid transport
WO2011076807A2 (en) 2009-12-23 2011-06-30 Novartis Ag Lipids, lipid compositions, and methods of using them
WO2011114678A1 (ja) * 2010-03-15 2011-09-22 国立大学法人山口大学 哺乳動物細胞への遺伝子導入効率の向上剤
US9750819B2 (en) * 2012-05-23 2017-09-05 Ohio State Innovation Foundation Lipid nanoparticle compositions and methods of making and methods of using the same
US9833416B2 (en) * 2014-04-04 2017-12-05 Ohio State Innovation Foundation Oligonucleotide lipid nanoparticle compositions, methods of making and methods of using the same
EP3329011B1 (en) * 2015-07-30 2019-12-18 Arcis Biotechnology Holdings Limited Method and composition
CN117481114A (zh) * 2023-10-27 2024-02-02 硅羿科技（上海）有限公司 纳米核酸农药、其制备方法和应用、以及核酸递送系统

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002529439A (ja) * 1998-11-12 2002-09-10 インビトロジェン コーポレイション トランスフェクション薬剤
JP2005527639A (ja) * 2001-11-02 2005-09-15 インサート セラピューティクス インコーポレイテッド Ｒｎａ干渉の治療的利用のための方法及び組成物
JP2005535653A (ja) * 2002-07-05 2005-11-24 リポクセン・テクノロジーズ・リミテツド 核酸ワクチン接種の免疫応答を高めるための方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283185A (en) * 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US6020317A (en) * 1993-02-19 2000-02-01 Nippon Shinyaku Co. Ltd. Glycerol derivative, device and pharmaceutical composition
US20030092180A1 (en) 2001-08-27 2003-05-15 David Lewis Inhibition of gene expression by delivery of small interfering RNA to post-embryonic animal cells in vivo
US5965542A (en) * 1997-03-18 1999-10-12 Inex Pharmaceuticals Corp. Use of temperature to control the size of cationic liposome/plasmid DNA complexes
GB9726398D0 (en) * 1997-12-12 1998-02-11 Isis Innovation Polypeptide and coding sequences
HUP9902217A3 (en) * 1999-06-29 2002-07-29 Szegoe Peter Polycation based bioconjugates and process for producing thereof
AU2002214854A1 (en) * 2000-10-25 2002-05-06 Inex Pharmaceuticals Corporation Lipid formulations for target delivery
WO2002060412A2 (en) * 2001-02-01 2002-08-08 Board Of Regents Stabilised polymeric aerosols for pulmonary gene delivery
US20030096414A1 (en) * 2001-03-27 2003-05-22 Invitrogen Corporation Culture medium for cell growth and transfection
US7713942B2 (en) * 2001-04-04 2010-05-11 Nordic Vaccine Technology A/S Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides
ES2559828T3 (es) * 2003-07-16 2016-02-16 Protiva Biotherapeutics Inc. ARN de interferencia encapsulado en lípidos
AU2005310131A1 (en) * 2004-11-17 2006-06-08 University Of Maryland, Baltimore Highly branched HK peptides as effective carriers of siRNA
US20070087045A1 (en) * 2005-10-14 2007-04-19 Industrial Technology Research Institute Lipid carrier and method of preparing the same
TW200800235A (en) * 2005-10-18 2008-01-01 Otsuka Pharma Co Ltd Carrier composition for nucleic acid transport

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002529439A (ja) * 1998-11-12 2002-09-10 インビトロジェン コーポレイション トランスフェクション薬剤
JP2005527639A (ja) * 2001-11-02 2005-09-15 インサート セラピューティクス インコーポレイテッド Ｒｎａ干渉の治療的利用のための方法及び組成物
JP2005535653A (ja) * 2002-07-05 2005-11-24 リポクセン・テクノロジーズ・リミテツド 核酸ワクチン接種の免疫応答を高めるための方法

Also Published As

Publication number Publication date
WO2007046356A1 (ja) 2007-04-26
EP1946761A1 (en) 2008-07-23
EP1946761A4 (en) 2012-01-25
CN101291678A (zh) 2008-10-22
CY1114586T1 (el) 2016-10-05
DK1946761T3 (da) 2013-04-15
US8030075B2 (en) 2011-10-04
RU2421227C2 (ru) 2011-06-20
EP1946761B1 (en) 2013-04-03
US20090258923A1 (en) 2009-10-15
MY149502A (en) 2013-09-13
KR20080059648A (ko) 2008-06-30
CA2624840A1 (en) 2007-04-26
AU2006305318A1 (en) 2007-04-26
CN102512689A (zh) 2012-06-27
PL1946761T3 (pl) 2013-08-30
SI1946761T1 (sl) 2013-06-28
EP1946761B8 (en) 2013-05-22
KR101324065B1 (ko) 2013-10-31
ES2412029T3 (es) 2013-07-09
PT1946761E (pt) 2013-05-27
AR057553A1 (es) 2007-12-05
TWI376225B (https=) 2012-11-11
RU2008119498A (ru) 2009-11-27
JPWO2007046356A1 (ja) 2009-04-23
AU2006305318B2 (en) 2011-08-25
HK1119956A1 (en) 2009-03-20
CN101291678B (zh) 2012-03-28
CN102512689B (zh) 2014-08-20
TW200800235A (en) 2008-01-01
BRPI0617449A2 (pt) 2011-07-26
HK1171689A1 (en) 2013-04-05

Similar Documents

Publication Publication Date Title
JP5349293B2 (ja) 即効型核酸送達用キャリアー組成物
JP5046952B2 (ja) 核酸送達用キャリアー組成物
US8338584B2 (en) Nucleic acid complex and nucleic acid delivery composition
US9090912B1 (en) Nucleic acid complex and nucleic acid-delivering composition
HK1171689B (en) Carrier composition for nucleic acid transport
HK1119956B (en) Carrier composition for nucleic acid transport
HK1139041B (en) Prompt nucleic acid delivery carrier composition

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090824

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120424

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120523

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120626

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120717

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150727

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 5046952

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees